With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Health financing and payment, results-based financing, social protection, conditional cash transfer programs, noncommunicable disease, maternal and child health
Amanda Glassman is chief operating officer and senior fellow at the Center for Global Development and also serves as secretary of the board. Her research focuses on priority-setting, resource allocation and value for money in global health, as well as data for development. Prior to her current position, she served as director for global health policy at the Center from 2010 to 2016, and has more than 25 years of experience working on health and social protection policy and programs in Latin America and elsewhere in the developing world.
Prior to joining CGD, Glassman was principal technical lead for health at the Inter-American Development Bank, where she led policy dialogue with member countries, designed the results-based grant program Salud Mesoamerica 2015 and served as team leader for conditional cash transfer programs such as Mexico’s Oportunidades and Colombia’s Familias en Accion. From 2005-2007, Glassman was deputy director of the Global Health Financing Initiative at Brookings and carried out policy research on aid effectiveness and domestic financing issues in the health sector in low-income countries. Before joining the Brookings Institution, Glassman designed, supervised and evaluated health and social protection loans at the Inter-American Development Bank and worked as a Population Reference Bureau Fellow at the US Agency for International Development. Glassman holds a MSc from the Harvard School of Public Health and a BA from Brown University, has published on a wide range of health and social protection finance and policy topics, and is editor and coauthor of the books Millions Saved: New Cases of Proven Success in Global Health (Center for Global Development 2016), From Few to Many: A Decade of Health Insurance Expansion in Colombia (IDB and Brookings 2010), and The Health of Women in Latin America and the Caribbean (World Bank 2001).
With current investment trends, by 2030, more than half the world’s children will not achieve a quality education. So, this year, global education financing is high on the agenda – at the G20, with the G7 accountability report, the World Bank’s World Development Report, and the upcoming replenishment conference for the Global Partnership for Education (GPE).
We would argue that investing in global health, at least along certain dimensions, is entirely consistent with President Trump’s philosophy of America First—a real opportunity for his administration to improve the security of the American people by pushing through some much-needed reform. In that spirit, we’ve put together a proposal for a new executive initiative under the Trump Administration. We call it PAHAA: Protecting America’s Health at Home and Abroad.
How do you make the case for US foreign aid to an Administration that has proposed slashing it? That was the task for Mark Suzman, Chief Strategy Officer and president of Global Policy and Advocacy for the Bill & Melinda Gates Foundation, when he recently accompanied Bill Gates to meetings at the White House. In this week's CGD podcast, Suzman gives us two very different versions of the fight against global poverty and disease—the perception and the reality. At an event called Financing the Future, he joined CGD experts Masood Ahmed, Amanda Glassman, and Antoinette Sayeh to discuss ways the development community can better convey their results.
Private investment in health R&D by pharmaceutical companies, charitable foundations, and venture capital firms, among others, can help to save lives and boost the health of entire regions. But some countries’ health governance infrastructures, management capacities, regulatory processes, and policy conditions are better equipped to utilize this private funding than others. What governance factors promote an investment-friendly environment for the private sector? And how can countries attract more private sector health financing?
Cost-effectiveness analysis (CEA) can help countries attain and sustain universal health coverage (UHC), as long as it is context-specific and considered within deliberative processes at the country level. Institutionalising robust deliberative processes requires significant time and resources, however, and countries often begin by demanding evidence (including local CEA evidence as well as evidence about local values), whilst striving to strengthen the governance structures and technical capacities with which to generate, consider and act on such evidence. In low- and middle-income countries (LMICs), such capacities could be developed initially around a small technical unit in the health ministry or health insurer. The role of networks, development partners, and global norm setting organisations is crucial in supporting the necessary capacities.
The long-awaited high-level panel report on the post-2015 development agenda called for a “data revolution” and proposes a new international initiative to get the job done. The proposed public-private initiative, called the Global Partnership on Development Data, would be responsible for developing a strategy to address gaps in critical information, improving data availability, and ensuring that quality baseline information is in place to measure and define progress against established development goals.
Attention presidential transition teams: The first hundred days of the new administration should kick start an ambitious agenda in global health alongside long-needed reforms to enhance the efficiency and effectiveness of US action. Building on our earlier work, we suggest seven priority actions within three broad categories.
Mobile applications – or ‘apps’ – seem to be the latest craze in mobile technology for global health programming. The proliferation of these apps is converging around a growing interests in open (and big) data, so you don’t have to look far to find creative ways they are being used to collect and display data in the development sector.
Noncommunicable diseases (NCDs) such as cancer, diabetes, respiratory and cardiovascular diseases, and mental illnesses are the leading cause of death and disability worldwide. The good news is that much of the NCD burden can be prevented through interventions that are affordable in most countries. The United States can help now by taking five low-cost or no-cost steps.
Millions Saved rigorously evaluates 22 programs from Haiti to Botswana, Peru to Pakistan, in order to understand what works in global health and why. Coauthor Amanda Glassman visits the CGD Podcast to share some of the book’s cases and takeaways.
Theory and some empirical evidence suggest the two goals – reproductive rights for women and women’s economic empowerment – are connected: reproductive rights should strengthen women’s economic power. But our understanding of the magnitude of the possible connection and the nature of any causal link (vs. coevolution or reverse causation) in different times and places is limited. In this note we summarize what we know up to now and what more we could learn about that connection, and set out the data requirements and methodological challenges that face researchers and policymakers who want to better understand the relationship.
Last week, Gavi, the Vaccine Alliance, completed a $7.5 billion replenishment to fund its work on immunization in the world’s poorest countries between now and 2020. Gavi’s next step is to ensure that the money is used as effectively as possible to save lives and improve health.
In the big federal countries where global disease burden is concentrated, most public money for health isn’t ultimately spent by the national ministry of health, the traditional counterpart for global health funders and technical agencies.